ARTICLE | Clinical News
CFDA reviewing Chi-Med's fruquintinib for advanced CRC
June 16, 2017 5:05 AM UTC
Hutchison China MediTech Ltd. (LSE:HCM; NASDAQ:HCM) said China FDA accepted for review an NDA for fruquintinib (HMPL-013) to treat advanced colorectal cancer (CRC). The acceptance triggers a RMB30.8 million ($4.5 million) milestone payment to Chi-Med from partner Eli Lilly and Co. (NYSE:LLY)...